Healthcare
Skye Bioscience, Inc.(SKYE)
Live Price
Offline$0.787
-1.63% today
1Y Change
-74.97%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $30.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -93.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Skye Bioscience, Inc. (SKYE) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $0.79 and down 75.0% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -93.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -93.2%, free cash flow -60.5% with operating margin 0.0% and ROIC -286.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SKYE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -93.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -6.5% | -17.9% | -9.6% |
2026 Mar 10, 2026 | -21.2% | -9.8% | -16.1% | -11.5% |
2025 Nov 10, 2025 | +3.0% | +2.8% | -1.4% | -14.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SKYE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SKYE Max Drawdown
-87.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SKYE and SPY.
Company Overview
Skye Bioscience, Inc.
NASDAQ Global Market
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
- Leadership
- Punit S. Dhillon
- IPO Date
- Nov 26, 2014
- Employees
- 16
- Street Address
- 11250 El Camino Real
- Mailing
- San Diego, CA, 92130
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 410 0266
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.6
Growth
- Revenue
- 0.0%
- EPS
- -93.2%
- Free Cash Flow
- -60.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -143.6%
- ROIC
- -286.6%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 3.30
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.